Expanded CDMO Biosurfit has recently expanded its contract development and manufacturing (CDMO) offerings, signaling readiness to service more diagnostics clients with turnkey manufacturing solutions.

Spinit Platform The Spinit point-of-care platform integrates hematology, immunoassays and clinical chemistry on a single device, presenting a compelling cross-test PoC solution to hospitals, clinics and reference labs seeking streamlined diagnostics.

European Footprint As a European diagnostics player with CE marking history and a focus on PoC, biosurfit is well-positioned to win contracts with EU-based healthcare providers and distributors seeking compliant, rapid diagnostics manufacturing.

Innovation Track With a pipeline built on microfluidics patents and prior innovation awards, biosurfit can target partnerships for advanced PoC assays and co-development opportunities leveraging its R&D strength.

Clinical Validation Recent CE marking for COVID antibody tests and institutional communications indicate ongoing regulatory and market validation, creating openings for trials, pilot deployments, and early access programs with health networks.